Jūlijs 2022: Saskaņā ar jaunākajiem Emergen Research veiktajiem pētījumiem globālais CAR T-šūnu terapijas tirgus 1.29. gadā sasniedza USD 2021 miljardus, un paredzams, ka prognozētajā periodā tiks reģistrēts CAGR 24.9 procenti. Paredzams, ka pieaugošā saslimstība ar vēzi visā pasaulē, kā arī pieaugošais vēža izraisītais mirstības līmenis prognozētajā periodā būs galvenie ieņēmumu pieauguma virzītāji globālajā CAR-T šūnu terapijas tirgū. Klīnisko izmēģinājumu darbību paplašināšanās straujā tempā, apvienošanās un pārņemšanas gadījumu izplatība, kā arī sākotnējo publisko piedāvājumu pievilcība ir faktori, kas veicina ieņēmumu pieaugumu globālajā CAR T-šūnu terapijas tirgū.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global AUTO T-šūnu terapija market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the AUTO T-šūnu terapija market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Par to liecina papildu nozīmīgi ziņojuma konstatējumi
In 2021, the segment of diffuse large B-cell limfoma was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with himērisko antigēnu receptoru T-šūnu terapija, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell ne-Hodžkina limfomas who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Galvenie uzņēmumi, kas pašlaik darbojas tirgū, ir sīkāk izpētīti šajā ziņojumā, kā arī to uzņēmumu profili, produktu portfeļi, paplašināšanas stratēģijas un stratēģiskās alianses. Daži šāda veida alianses piemēri ietver apvienošanos un pārņemšanu, sadarbību un kopuzņēmumus. Papildus tam tiek sniegta informācija par uzņēmuma sasniegumiem un finansiālo stāvokli, kā arī ieskats uzņēmuma tirgū un globālajā pozīcijā.
Uzņēmumi, kas profilēti globālajā CAR T-šūnu terapijas tirgū:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd. un Eli Lilly and Company .
Lasiet vairāk par globālo CAR T-Cell Therapy tirgus ziņojumu vietnē: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
